MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
22.33
-0.28
-1.24%
After Hours: 22.33 0 0.00% 17:53 04/19 EDT
OPEN
22.52
PREV CLOSE
22.61
HIGH
22.76
LOW
21.75
VOLUME
965.83K
TURNOVER
0
52 WEEK HIGH
42.48
52 WEEK LOW
20.67
MARKET CAP
2.77B
P/E (TTM)
-8.0558
1D
5D
1M
3M
1Y
5Y
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 1d ago
TURNSTONE BIOLOGICS APPOINTS WILLIAM WADDILL TO ITS BOARD OF DIRECTORS
Reuters · 5d ago
Weekly Report: what happened at ARWR last week (0408-0412)?
Weekly Report · 6d ago
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
Seeking Alpha · 04/10 16:03
Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results
TipRanks · 04/10 13:55
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler
TipRanks · 04/08 10:37
Weekly Report: what happened at ARWR last week (0401-0405)?
Weekly Report · 04/08 09:12
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.